Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

计划入组 45 人 · 首次发布于 2023 年 9 月 25 日

CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

首次发布于 2025 年 8 月 22 日

Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes

计划入组 18 人 · 首次发布于 2022 年 11 月 25 日

CELZ-201

CELZ-201-DDT

CELZ-001

Creative Medical Technology

United States

Nemysis Ltd.

Ireland

Schaper & Brümmer GmbH & Co. KG

Germany

Creative Medical Technology Reports 93% Response Rate for Ultrasome™ in Knee Osteoarthritis Pilot Study

Creative Medical Receives U.S. Patent Allowance for Exosome-Based Type 1 Diabetes Immunotherapy

WHO Approves "Olastrocel" as International Name for Creative Medical's Lead Cell Therapy CELZ-201